Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Fibrosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 13Ifosfamide 10Radiotherapy 6Sunitinib 3pegfilgrastim 2Trabectedin 2Radiotherapy, Conformal 2Nivolumab 2Methotrexate 2Ipilimumab 2Imatinib Mesylate 2Filgrastim 2Etoposide 2Cisplatin 2Chemotherapy, Adjuvant 2tremelimumab 1temsirolimus 1soblidotin 1saracatinib 1romidepsin 1ribociclib 1reolysin 1perifosine 1pembrolizumab 1pazopanib 1olaratumab 1montanide ISA 51 1liposomal doxorubicin 1indolepropanol phosphate 1exatecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Histiocytoma, Malignant Fibrous × soblidotin × Clear all
NCT00064220 2012-05-16

Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

Daiichi Sankyo

Phase 2 Completed
Sarcoma

Hemangiopericytoma, Malignant, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡